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Abstract
Objectives This review aims to establish the impact on
conventional angiography and endovascular intervention
of contrast-enhanced magnetic resonance angiography
(CE-MRA) and contrast-enhanced computed tomography
angiography (CE-CTA) on a background of evolving tech-
nology, changing clinical requirements and resulting clinical
repercussions.
Methods The angiographic and interventional caseload was
prospectively recorded between 1997 and 2010, along with
the CE-MRA and CE-CTA caseload. Waiting times and the
marginal cost analyses for 2001 and 2009 were also pro-
spectively established.
Results Conventional diagnostic angiographies declined
from a peak of 847 to 121 per year while endovascular
interventions continue in similar numbers. CE-MRA
increased from effectively none initially to 620 per year
while CE-CTA has currently risen to 396 per year. Total
diagnostic study numbers have increased but at reduced
cost. Various influences are clear, including on-site mo-
dality availability, capability and accuracy along with
impact of new therapies, research studies and adverse
events.
Conclusions Vascular imaging has undergone a metamor-
phosis in little over a decade because of CE-MRA and CE-
CTA. With waiting times significantly reduced since the
start of the study and the cost-effectiveness of both CE-
MRA and CE-CTA as primary diagnostic investigations
established, further development of these services is
inevitable.
Main Messages
• The availability of CE-MRA and CE-CTA has reduced the
need for conventional angiography.
• Both waiting times and the marginal cost analyses for
CE-MRA and CE-CTA have reduced.
• The impact of new therapies, research studies (e.g. ASTRAL)
and adverse events is illustrated.
Keywords Contrast-enhanced magnetic resonance
angiography (CE-MRA) . Contrast-enhanced computed
tomography angiography (CE-CTA) . Vascular imaging
Introduction
The imaging modalities of choice in vascular imaging have
changed considerably over the last decade, with advances in
magnetic resonance imaging (MRI) and computed tomog-
raphy (CT) technology coupled with the increasing avail-
ability of MRI and multislice CT scanners capable of these
forms of non-invasive angiography. Our aim in this work
has been to establish the impact of the evolving technologies
of conventional angiography, interventional angiography,
contrast-enhanced MRI angiography (CE-MRA) and
contrast-enhanced CT angiography (CE-CTA) on the re-
spective workloads of conventional invasive angiography
and vascular interventional procedures. We have also related
this to the clinical requirements with emerging clinical
repercussions in a referral centre along with the impact on
clinical practice.
CE - MRA
CE-MRAwith gadolinium-based contrast agents has emerged
as a realistic non-invasive alternative to traditional invasive
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diagnostic angiography. As well as the development of
contrast-enhanced techniques, the ancillary technological
advances in MRI software and hardware (gradient coils and
phased array coils) plus bolus detection methods, stepping
table techniques and parallel imaging have shortened exami-
nation times and improved image quality significantly. The
use of MRI fulfils the ALARA principle (‘as low as reason-
ably achievable’) as regards minimising exposure to ionising
radiation but there is also a favourable side effect profile in
respect of the contrast agents used with extremely few patients
experiencing adverse events [1, 2], with many of these just mild
side effects such as nausea, vomiting or urticaria [3]. Only a
limited number of reports of contrast-induced toxicity are avail-
able, with the majority of studies showing no evidence of
deterioration in renal function [4]. Recently an association
between the use of certain linear chelate gadolinium-based
contrast agents (GBCAs) in patients with severe renal impair-
ment (mainly those requiring dialysis) and the potential devel-
opment of the rare, recently recognised condition nephrogenic
systemic fibrosis (NSF) has been reported [5], leading to these
particular linear chelate agents being contra-indicated in acute
kidney injury and severe chronic renal failure. Cyclic gadolin-
ium chelates have not been specifically contra-indicated.
Investigations with surgical/angiographic correlation have
shown CE-MRA to have a high sensitivity and specificity for
detection of peripheral arterial steno-occlusive disease, and
100 % sensitivity and specificity for detection of aortic or iliac
aneurysms [6]. CE-MRA has hence become accepted for non-
invasive angiographic studies that can be performed on an
out-patient basis, with high accuracy, for example in evalua-
tion of the peripheral (lower limb) arterial system [7]. There
are some limitations, which may curb the use of MRI, includ-
ing cardiac pacemakers and resynchronisation devices, ferro-
magnetic intracranial aneurysm clips, shrapnel injuries,
claustrophobia and steel intravascular stents. The largest in-
crease in workload was anticipated in patients undergoing CE-
MRA of the abdominal aorta, iliac vessels and lower limb run-
off. This is because traditionally arteriography of the aortoiliac
and lower limb run-off assessing patients with peripheral
arterial occlusive disease (PAOD) has contributed the largest
proportion of conventional diagnostic angiography workload.
We anticipated that this area would show a clear benefit from
the transfer of primary investigation to a predominantly out-
patient non-invasive test such as CE-MRA. An example of the
use of CE-MRA for assessment of PAOD in our institution is
shown in Fig. 1.
Fig. 1 Three-station ‘bolus-
chase’ moving-table lower limb
MR angiograms. Left study (a)
in a diabetic patient with calf
claudication shows preserved
aortoiliac and femoropopliteal
segments but typical occlusive
below-knee tibial disease. Mid-
dle study (b) in bilateral clau-
dicant with absent right femoral
pulse shows occluded right
common and external iliac ar-
teries with reasonably preserved
infra-inguinal run-off on that
side, whereas on the left while
the iliac arteries are reasonable
there is stenotic femoral artery
disease in the proximal thigh.
Right study (c) in a claudicant
patient with impaired left fem-
oral pulse reveals shelf-like
lower aortic stenosis, stenotic
left iliac disease and an occlud-
ed right superficial femoral ar-
tery but preserved infrapopliteal
run-off. Note that in these non-
critical claudicant patients there
is little ‘venous contamination’,
and these MRA images are as
presented immediately after ac-
quisition with automated MIP
post-processing and stitching to
give an instant overview vas-
cular map of multilevel disease
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CE-CTA
CE-CTA has also advanced rapidly in the last decade with
the advent of multislice scanners with increasing numbers of
detector rows, accompanied by bolus detection methods and
increasingly rapid rotation of CT gantries that have allowed
increased spatial resolution and extended coverage. These
technological advances have improved CE-CTA accuracy,
and 64-detector row CE-CTA has been shown to be superior
to 4- or 16-detector row studies demonstrating high sensi-
tivity and specificity, in comparison with digital subtraction
angiography [8]. CT has some advantages compared to MRI
in that patient features such as pacemakers pose no problem
and intravascular stents including those made of steel are
well assessed. However, CT angiographic examinations are
high-radiation-dose studies limiting their repeated use in
younger patients while iodine-based contrast media carry a
risk in patients with renal impairment lest contrast-induced
nephrotoxicity (CIN) further damages kidney function. Con-
versely for those patients with no residual renal function
maintained on dialysis (and hence not at risk of CIN) then
CE-CTA can be offered as an alternative to CE-MRA if
administration of GBCA is thought high risk. Aside from
the preclusion of those with renal impairment, the adverse
event rate experienced with low-osmolar iodinated contrast
media has been demonstrated to be low in out-patients, with
most of these experiencing only mild side effects [3].
From an interpretation perspective heavily calcified arte-
rial disease can be challenging to accurately evaluate on
CTA; metal prostheses may produce obscuring artefact and
although CE-CTA generally assesses stents well, small-
calibre stents remain challenging to analyse. In many insti-
tutions, CE-CTA is employed as the initial study of choice
for investigation for vascular disease, particularly given the
now widespread availability of multislice technology.
Methods
This study was conducted in a 900-bed teaching hospital
providing vascular surgical services as well as a regional
renal medicine unit over a 12-year period. The contrast-
enhanced MRI angiography (CE-MRA) service was initially
introduced in June 1998 after a CE-MRA-capable MRI
system was installed—a 1.5-T Philips Gyroscan ACS-NT
MRI Scanner (Philips Medical Systems, Best, The Nether-
lands), including a contrast pump injector (Medrad Spectris,
Medrad, Indianola, PA). Following an upgrade in 2002, the
scanner was enhanced with a software and table upgrade to
allow moving table peripheral angiography plus phased
array coils enabling implementation of parallel imaging
techniques. A second MRI scanner was added in 2009—a
1.5-T Siemens Magnetom Avanto (Siemens Healthcare,
Erlangen, Germany), again with a Medrad contrast pump
injector and a dedicated peripheral vascular phased array
coil. Several generations of CT scanners have been
employed in this time, the single detector row scanner
initially installed in 1997 that was effectively unable to
perform extended CTA studies being supplemented by a
four-detetctor row Siemens Somatom 2 in 2002 upon which
lower limb angiographic studies could be performed, al-
though with limited slice resolution. A 64-detector row
Toshiba Aquilion CT scanner (Toshiba Medical Systems,
Tochigi-ken, Japan) equipped with a Medrad Stellant dual-
head contrast pump injector was installed in 2007, replacing
the original single-detector-row machine and allowing thin
collimation peripheral run-off studies. A second identical
64-slice Toshiba scanner was installed in 2009, bringing
the complement of CT scanners to three: one 4 detector
row and two 64 detector row.
The baseline angiography and interventional vascular case-
load was established for the year June 1997 to the end of May
1998. The subsequent workload to the end of May 2010 was
prospectively collated each year and comparison drawn with
the CE-MRA and latterly CE-CTA numbers. Latterly CE-
CTA numbers were also collected for additional comparison.
The numbers of investigations, procedures performed and
body area examined (grouped into aortic arch and carotid
arteries, thoracic aorta, renal vascular studies, abdominal aor-
ta, aortoiliac and lower limb arterial run-off plus venographic
studies) were recorded. CT pulmonary angiograms and more
recently CT coronary angiograms have been specifically ex-
cluded, with only CT angiographic vascular studies generated
via the vascular service evaluated. Ultrasound is not employed
for primary investigation of lower limb peripheral vascular
disease in our institution (ultrasound is reserved for graft
surveillance), and hence has not been studied.
Changes in waiting times over the decade have been
compared to baseline, whilst a marginal cost analysis for
conventional diagnostic angiographic procedures was made
accounting for consumables (contrast media, film, archive
media, catheters, guide wires etc.), staffing (radiographers,
nursing staff and radiologist time) and hospital bed costs.
Marginal cost for CE-CTA and CE-MRAwas also calculat-
ed taking similar relevant parameters into consideration.
The equivalent radiation dose for CE-CTA performed on
our 64-detector-row scanner was estimated by calculating
the mean of the effective dose of all such studies performed
in the final month of data acquisition [9, 10].
The angiographic, CT and MRI workload was evaluated
up to May 2010 using the Radiology Information System
(RIS) and compared with the workload in May 1998 using
the vascular theatre logs. Alterations in workload pattern
have been correlated historically to the changes in the im-
aging environment at the local and national/international
level that have been perceived to have had an impact.
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Results
The study period, numbering 13 years in total (including
baseline years), runs from 1 June 1997 to 31 May 2010,
duringwhich time there have been 8,769 invasive angiograph-
ic procedures, of which 5,105 were diagnostic vascular and
3,664 were interventional vascular procedures. In the same
period there were 6,859 CE-MRA procedures, with the overall
number of vascular studies numbering 16,872. There was a
year-on-year rise in the number of CE-MRA studies per-
formed each year from 1997/98 (13 studies) to 2002/03 (760
studies) with a reciprocal 50.4 % drop in conventional diag-
nostic angiography during the same period (847–328 studies,
Fig. 2). The number of interventional angiographic procedures
remained largely constant. A small drop in the number of CE-
MRA studies occurred after 2003/04.
Comparison of monthly angiographic workloads at the
start and end of data acquisition demonstrated stark differ-
ences in practice. In May 1998, 52 conventional diagnostic
angiograms were performed, along with 22 invasive inter-
ventional procedures. In May 2010, 3 conventional diag-
nostic angiograms were performed, along with 23 invasive
interventional procedures. Meanwhile 40 CE-MRA studies
and 23 CE-CTA studies were undertaken in this period.
Figure 3 depicts the numbers of CE-MRA studies, with
the timing of the FDAwarning regarding the use of GBCAs
and presentation of initial results from the ASTRAL trial
highlighted (see later discussion).
The number of renal angiographic investigations per-
formed is detailed in Fig. 4, demonstrating a very rapid
initial growth in renal CE-MRA in particular and subse-
quent decline on a background of relatively constant low
numbers of invasive renal angiograms, angioplasties and
angioplasty/stent procedures performed. In 2009/10, 50 of
the 84 CE-MRAs (59.5 %) performed were for investigation
of hypertension (red arrow in Fig. 4). In 2002/03, exact
referral patterns are difficult to ascertain because of a change
in the Radiology Information System coding, but around
75 % of studies were for investigation of possible renovas-
cular disease (black arrow in Fig. 4). The number of CE-
MRA studies by body region is demonstrated in Fig. 5, with
the largest increase in studies of the abdominal aorta, iliac
arteries and lower limb run-off, with a reciprocal drop in the
conventional invasive angiograms performed for this pur-
pose. Until 2003, the numbers of total radiological vascular
investigations and procedures showed a steady rise, and
have since remained roughly constant to the present day
(Fig. 6).
Waiting times have varied over this period, with the wait
in 1997 for a non-urgent conventional invasive angiogram
for investigation of claudication peaking at 7 months. This
had reduced to 3 weeks by 2003 and stands at a maximum
of 3 weeks currently. The waiting period for CE-MRA has
varied with popularity and availability of the technique,
rising to around 4 months in 2003 following the service’s
inception and prior to the second scanner acquisition. This
has also reduced to less than a 3-week wait currently, with
CE-CTA requiring a similar waiting time for non-urgent
out-patient studies.
Marginal cost analyses were performed in 2001 and
2009, with costs for CE-MRA actually reducing from
£149 (€185) per study to around £100 (€125) currently.
Fig. 2 CE-MRA, conventional diagnostic and interventional
angiography
Fig. 3 CE-MRA renal studies
Fig. 4 Total numbers of renal investigations
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Conventional diagnostic angiography, including the cost of
a day or overnight bed, cost £515 (€640) in 2001, and this
was similar in 2009. The CE-CTA marginal cost was esti-
mated at £68 (€85) per study in 2009. The overall cost of the
diagnostic angiography service is demonstrated in Fig. 6,
with the individual costs of conventional diagnostic angiog-
raphy, CE-MRA and CE-CTA included.
The mean effective dose for a selection of peripheral
angiograms was performed using the dose-length product
[11], with a mean dose of 16.6mSv utilising an ICRP 60-
tissue weighting factor for body CT [12, 13].
Discussion
The advent of non-invasive vascular imaging using CE-
MRA and CE-CTA has resulted in non-invasive alternatives
to invasive diagnostic angiography providing excellent
quality three-dimensional images whilst avoiding the poten-
tial complications associated with invasive procedures. Both
CE-MRA and CE-CTA are superior to ultrasound in their
ability to image the entirety of the pertinent vascular tree,
avoiding compromise of image quality by depth in the body
or interposed bowel gas. Another major advantage over
ultrasound is the depiction of the vascular tree in a familiar
angiographic format with very low inter-observer variability
enhancing clinical credibility and allowing straightforward
discussion in the multidisciplinary team environment. The
overall impact of CE-MRA and CE-CTA in our institution
has been a marked reduction in the conventional diagnostic
angiography workload, with extensive use of CE-MRA
and more recently CE-CTA in a wide range of clinical
scenarios, with tailoring of modality to individual cases
bearing in mind the ALARA principle. The volume and
choice of the type of examinations performed have been
influenced by modality availability, clinical trends and
technical developments, as well as consequential theo-
retical and real adverse effects. The impact has varied
over time in relation to various factors as per the following
discussions.
Renovascular imaging
A steady increase in diagnostic vascular imaging activity
was apparent up until 2002/03, with an additional 382
patients (32.4 %) examined overall in the year 2001/02 as
compared to 1997/98. This is in part due to a proliferation in
renovascular imaging in this period. Whilst only 22 conven-
tional renal angiograms were performed in the year prior to
the advent of CE-MRA in 1997/98 for investigation of
suspected renal artery stenosis, in 2002/03 377 renovascular
studies were undertaken, accounting for almost all the in-
crease in diagnostic vascular imaging. The majority were for
investigation of possible atherosclerotic renovascular dis-
ease as a cause of renal impairment with or without hyper-
tension, mainly from the renal medicine service and
cardiology. Indeed referrals also came from renal physicians
and cardiologists based at other institutions in and around
the city. This was due to the non-invasive nature, good
sensitivity and specificity relative to digital subtraction an-
giography, and great superiority of CE-MRA compared to
Doppler ultrasound [14]. These factors dramatically reduced
the threshold for investigation of suspected renovascular
disease. A reduction in the total number of renal diagnostic
procedures performed at our site in 2002/03 is accounted for
partly by a change in service provision with another city site
starting a CE-MRA service. However, another factor is that
a large backlog of chronic kidney disease patients attending
clinics hitherto not investigated had by then been scanned
Fig. 5 CE-MRA by body site
Fig. 6 Cost of the diagnostic
angiography service compared
to total number of studies
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for suspected renovascular disease, with largely only new
presentations being referred for CE-MRA subsequently. The
number of renal revascularisations remained consistently
low reflecting a local scepticism among the renal physicians
regarding the value of revascularisation although they were
clearly keen to document the nature of disease in their
patients. This situation is likely to continue given the effi-
cacy of modern medical management and slower rate of
renal function decline than previously believed. Renal vas-
cular intervention in our institution is now largely reserved
for patients with recurrent ‘flash’ pulmonary oedema, rapid
renal functional decline or uncontrolled malignant hyperten-
sion despite maximal medical therapy, although the new
technique of renal denervation may reverse this [15, 16].
Development of another CE-MRA capable site also contrib-
uted to the drop in total number of studies at our institution
in 2002/03 (red arrow in Fig. 3). The Angioplasty and Stent
for Renal Artery Lesions trial (ASTRAL) in which our
centre participated has been by far the largest trial in ath-
erosclerotic renovascular disease (ARVD), recruiting 806
patients [15]. The trial was designed to address whether
renal revascularisation with balloon angioplasty/stent could
prevent progressive renal failure among ARVD patients.
The trial found substantial risks but no evidence of a worth-
while clinical benefit from revascularisation in patients with
ARVD. However, the effect of the dissemination of the
results of the ASTRAL trial was actually minimal at our
institution (blue arrow in Fig. 3), largely because of local
renal physician scepticism and the prior significant reduc-
tion in imaging of patients with renal impairment as a result
of newly recognised GBCA toxicity in patients with severe
renal failure, a phenomenon discussed below [17].
Nephrogenic systemic fibrosis
A decrease in the total number of CE-MRA studies was
observed in 2007/08, reducing from 580 to 509 studies (a
12.2 % drop). This was largely due to the large relative
reduction in renal studies in this period, demonstrated in
Fig. 5, attributable to the initial reporting in May 2006 of an
association between the use of GBCAs and the development
of nephrogenic systemic fibrosis (NSF). NSF is a serious
disorder characterised by hardening and thickening of the skin
and body tissues. Initially described as ‘scleromyxoedema-like
skin thickening’ affecting the limbs and trunk [18], it was
solely seen in dialysis patients and was first titled nephrogenic
fibrosing dermopathy [19], subsequently renamed nephro-
genic systemic fibrosis. Reviews noted the universal setting
of renal failure but not the cause [20–22]. Prior to this there
had been no concerns regarding the use of GBCA in haemo-
dialysis patients, with prompt excretory rates at haemodialysis
following GBCA administration and initial research suggest-
ing GBCAs in the doses usually employed had an excellent
safety profile and were less nephrotoxic than iodinated con-
trast [5, 23]. This led to widespread use of CE-MRA in
patients with impaired renal function where examinations
employing iodine-based contrast media engender significant
risk. In 2006, GBCAs were first proposed as a potential factor
in the development of NSF [5], and research indicated an
association with the recent use of GBCAs, particularly in high
dose on a background of chronic dialysis-dependent renal
failure (or less commonly acute renal failure) [24]. Further
evidence was the discovery of traces of gadolinium in tissue
biopsies from affected patients [25, 26]. A United States Food
and Drug Administration warning regarding the use of
GBCAs was released in June 2006 [27]. Currently, the linear
chelate compounds (gadopentetate dimeglumine, gadodia-
mide and gadoversetamide) are contra-indicated in those
patients with a glomerular filtration rate (GFR) of less than
30 ml/min and avoiding GBCA use with other compounds is
recommended unless absolutely clinically necessary and then
with minimum dose. This has led to a change in clinical
practise in order to identify those at risk such as those with
diabetes, hypertension or on nephrotoxic medication in whom
knowledge of GFR is important prior to decision making on
imaging mode [28]. Recent reviews indicate that the risk of
NSF can be eliminated by careful management of risk factors,
with up to a ten-fold risk reduction by elimination of just one
risk factor [29]. This reduction in the applicability of CE-
MRA has spurred the development of newer non-enhanced
MRA techniques, such as arterial spin labelling for aortic or
renal imaging, as well as ECG-gated 3D partial-Fourier fast
spin echo sequences in the evaluation of peripheral arterial
disease [30, 31] for those patients with end-stage renal disease.
Role of CT angiography
The increase in the use of CE-CTA over the final 5 years of
the study period merits discussion, with an increase in CE-
CTA (excluding CT pulmonary angiography and CT coro-
nary angiography) from 122 studies in 2005/06 to 396
studies in the final year of data collection. This is a
technology-driven phenomenon with utilisation having been
revolutionised by multidetector row scanners with 16 or more
detector rows. A wide range of clinical applications are de-
scribed, including traumatic injuries, embolic phenomena,
aneurysms and atherosclerotic disease [32]. Figure 7 demon-
strates a clinical application of CE-CTA. Good accuracy has
been demonstrated with 4- and 16-slice scanners, but it has
particularly been with the advent of ‘64-slice’ scanners that
CE-CTA has become a more mature and robust modality. In
the lower extremities accuracy has been shown to be good for
claudicant patients although its role in critical lower limb
ischaemia remains relatively controversial and unproven [8,
33]. CE-CTA can play a useful role in those patients estab-
lished on renal dialysis with no residual renal function, as
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there is no concern regarding potential contrast-induced ne-
phropathy although potential adverse effects on the myocar-
dium and volume loading remain, whilst difficulties in
interpretation are encountered due to heavily calcification
significantly obscuring the lumen, particularly in small ves-
sels. This calcification is of itself useful information to the
surgeon as regards the quality of the vessels for clamping and
anastomosis, although there is anecdotal evidence that it may
unnecessarily dissuade surgeons from operating and blooming
artefacts can certainly make calcified plaques appear much
more pronounced than in physical reality. CE-CTA certainly
offers improved visualisation of metallic stents and stent grafts
and their lumens compared to CE-MRA though evaluation of
very small calibre stents remains problematic. CE-CTA is
preferred in patients in whom CE-MRA is contra-indicated,
such as those with pacemakers, other metallic implants or
claustrophobia. Despite the requirement for administration of
iodine-based contrast media and exposure to ionising radia-
tion [34], patients experience fewer adverse events than from
either contrast angiography or CE-MRA [35]. The risk of
contrast-induced nephropathy can be reduced by prior volume
expansion with saline or sodium bicarbonate, and careful
monitoring of Metformin use [4]. Though a lesser radiation
burden than digital subtraction angiography (DSA), CE-CTA
is a relatively high-dose procedure, on average 13.7 mSv per
study using a 4-slice scanner [36, 37]. This compares with a
value of around 12 mSv on average for conventional abdom-
inal angiography with DSA, although this figure varies
Fig. 7 Three-dimensional
volume-rendered image and
curve planar reformat (CPR)
along vessel centreline for right
iliac arteries from CTA per-
formed for assessment of ab-
dominal aortic aneurysm to
assess potential for endovascu-
lar repair. Infrarenal aneurysm
terminates at the aortic bifurca-
tion and CPR (delineated by
green line on VR image) dem-
onstrates satisfactory calibre
right iliac access without ste-
notic disease
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between 4 and 48 mSv depending on the difficulty of the
procedure and operator expertise [38, 39]. The CT angiogra-
phy dose is higher with more modern 64-slice scanners, and
analysis of our own examinations indicates an average dose of
16.6 mSv per study. However, it should be noted that this is
based on ICRP 60 [12]. There is no currently accepted con-
version factor for peripheral angiograms and the use of ICRP
103 recommendations would likely significantly increase this.
A number of dose reduction strategies are available, such as
tube current modulation and alteration of the tube current and
voltage dependant on the patient’s body mass index [40] and
more recently iterative reconstruction techniques [41]. Lack of
information on flow dynamics is a major drawback of CT in
comparison to both CE-MRA and DSA.
Overall diagnostic demand
Interestingly, despite large variations in angiographic mo-
dality choice and availability over a decade, then bar the
renal angiographic threshold being reduced, the overall
number of diagnostic investigations through the vascular
surgical service has remained largely constant, now with a
total number of studies usually between 1,200 and 1,400 per
year. The only significant departure from this, 1,014 studies
performed in 2004/05, was a result of transfer of a propor-
tion of CE-MRA services to two further city sites within the
health board, which commenced a CE-MRA service. This
suggests that demand for services has not significantly al-
tered, but evolution of technology and its availability has
necessitated change.
Impact on interventional services
The significant shift to non-invasive vascular imaging is
well demonstrated by comparison of monthly diagnostic
workloads at the start and end of data acquisition, with
minimal numbers of invasive conventional angiography
now performed, largely replaced by non-invasive CE-
MRA and CE-CTA. Although the number of interventional
vascular cases has remained broadly constant over the study
period, there has been a significant trend to an increase in
the complexity of time-consuming cases, such as endovas-
cular aneurysm repair (EVAR). Meanwhile there has been a
reduction in more straightforward angioplasty (although a
lesser role than previously thought in claudication due to
femoropopliteal disease) and thrombolysis. Despite the con-
siderable increase in the time required in the interventional
suite to perform procedures such as EVAR, the uptake of
non-invasive angiography techniques has helped free up the
time in the vascular radiology theatre suite previously re-
served for routine diagnostic angiography, allowing the
more extensive access required for complex interventional
procedures. The relatively constant number of interventional
procedures is likely a combination of the reduction in infra-
inguinal angioplasties for claudication in line with local
practice and the reduction in thrombolysis.
Cost analysis and impact on departmental workflow
Figure 6 depicts the trend of generally constant diagnostic
activity and constantly reducing cost, demonstrating the
cost-effectiveness of these imaging techniques. Coupled
with their non-invasive nature, the benefit of performing
the majority of diagnostic vascular imaging by CE-MRA
or CE-CTA is clear. This cost analysis does not include the
initial outlay on equipment, with our department now host-
ing two CE-MRA capable units and three multi-slice CT
scanners in line with the general demand for these modali-
ties, which represents a significant investment. Cost analy-
sis, though complex, plays an important role in determining
future departmental imaging strategies, allowing projections
of costs in order to help plan future provisions for imaging
whilst enabling analysis of the impact of previous changes
in use of imaging modalities and referral patterns, as dem-
onstrated by our data. Planning for any future structural
changes in a department should be undertaken, for instance
leaving space for additional scanners in new buildings or
earmarking obsolete or unused areas for a change in use.
Waiting times also impact significantly on a department’s
workflow and interaction with other departments, and con-
sideration of extended working hours, clear indications for
patient referral, the need for additional scanners and general
measures such as sequence rationalisation in MRI all play a
part in reducing this as much as possible. Invasive diagnos-
tic angiography conventionally required at least a day bed or
even overnight stay, adding additional strain in terms of
resources along with adequate nursing and medical cover.
CE-CTA and CE-MRA have removed this requirement,
with procedures performed as an out-patient with no need
for an extended hospital stay and a vastly reduced incidence
of post-procedural complications.
Educational impact
The potential for marked changes in diagnostic practice is
demonstrated in Fig. 2. One radiology educational conse-
quence has been that the drop in diagnostic angiography has
led to more limited opportunities to acquire basic vascular
skills although this is a small change compared to other
alterations in interventional vascular radiology training.
Continuing medical education plays a crucial role in ensur-
ing radiologists keep apace with this, both through formal
learning or teaching but also via self-directed learning.
Trainee radiologists should be aware of the potential for
such alterations in practice and the requirement to be flex-
ible throughout their career, underlining the need for good
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basic training in all modalities and continuing medical edu-
cation. By keeping abreast of current publications and
guidelines and maintaining good links with the reporting
clinicians, established radiologists will be better placed to
anticipate changes in modality demand and develop
approaches to ensure the standard of care is maintained.
Conclusion
Vascular imaging has undergone a significant metamorpho-
sis in little over a decade, with a major decline in conven-
tional diagnostic angiography and a corresponding boom in
CE-MRA and more recently CE-CTA. The modalities each
have their strengths and weaknesses but they have become
firmly established and we have demonstrated cost-effective,
time-effective and safe diagnostic angiographic use.
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